BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Executive Summary

• BriaCell Therapeutics announced the addition of three major cancer centers—Dartmouth Cancer Center, Cedars‑Sinai Medical Center, and Winship Cancer Institute of Emory University—to its pivotal Phase 3 trial of Bria‑IMT in metastatic breast cancer.
• The trial now has 79 clinical sites across 23 U.S. states enrolling patients, accelerating enrollment ahead of the anticipated top‑line data readout in H1‑2026.
• Bria‑IMT plus an immune checkpoint inhibitor continues to target overall survival as the primary endpoint and retains FDA Fast Track designation.

Key Details

• New Sites Added: Dartmouth Cancer Center (Hanover, NH), Cedars‑Sinai Medical Center (Los Angeles, CA), Winship Cancer Institute of Emory University (Atlanta, GA).
• Current Site Count: 79 sites in 23 U.S. states actively enrolling patients.
• Existing Notable Sites: Mayo Clinic, Los Angeles Cancer Network, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Blood Specialists, Texas Oncology‑Baylor Charles A. Sammons Cancer Center.
• Trial Design: Bria‑IMT + immune checkpoint inhibitor vs. physician’s choice; primary endpoint is overall survival (OS) based on 144 patient deaths.
• Regulatory Status: Bria‑IMT combination regimen holds FDA Fast Track designation.
• Data Timeline: Interim analysis after 144 events; top‑line results expected as early as the first half of 2026.
• CEO Quote: “We are encouraged by the strong engagement from major academic and leading community cancer centers…the addition of these clinical sites will further accelerate patient enrollment…” – Dr. William V. Williams, President & CEO.

Notable Quotes

“We expect the addition of these clinical sites will further accelerate patient enrollment in BriaCell’s pivotal Phase 3 study of Bria‑IMT regimen in MBC and support our mission to bring this therapy to patients with significant unmet medical needs.” – Dr. William V. Williams, President & CEO.